AZNAstraZenecaRunning, no new patients
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Stage II-IIIB Non-small Cell Lung Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 188 (final count)
- Started
- Mar 6, 2023
- Main results expected
- Nov 22, 2029
- Fully finished
- Nov 22, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Estimate the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].
Measured over: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 5 years.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05526755 · record last updated 2026-08-03 · checked 2026-11-09 15:47 UTC